Published in Community Ment Health J on October 01, 2002
Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol (1991) 22.01
What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry (1996) 11.03
Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives. J Consult Clin Psychol (1999) 2.60
Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry (1994) 1.55
Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. J Psychiatr Res (2001) 1.18
Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry (1997) 1.10
Cognitive deficits and cognitive training in schizophrenic patients: a review. Acta Psychiatr Scand (1999) 1.07
Assessment of the dysexecutive syndrome in schizophrenia. Psychol Med (1997) 0.97
Frontal/executive impairments in schizophrenia. Schizophr Bull (1996) 0.95
Treatment of cognitive dysfunctions and behavioral deficits in schizophrenia. Schizophr Bull (1992) 0.93
Imaging as a tool in exploring the neurodevelopment and genetics of schizophrenia. Br Med Bull (1996) 0.88
Flexibility, inhibition, and planning: frontal dysfunctioning in schizophrenia. Brain Cogn (2000) 0.86
Cognitive rehabilitation for schizophrenia: is it possible? Is it necessary? Schizophr Bull (1992) 0.86
The behavioural assessment of the dysexecutive syndrome as a tool to assess executive functions in schizophrenia. Clin Neuropsychol (1999) 0.86
Cognitive remediation in schizophrenia: should we attempt it? Schizophr Bull (1992) 0.84
Whither cognitive-behavioral therapy for schizophrenia? Schizophr Bull (1992) 0.81
Neurodevelopmental risk factors in schizophrenia. Braz J Med Biol Res (2001) 0.79
Community-based care of individuals with schizophrenia. Combining psychosocial and pharmacologic therapies. Psychiatr Clin North Am (1993) 0.79
Review: treatment of schizophrenia. State of the art. Eur Arch Psychiatry Clin Neurosci (1996) 0.78
Effects of traumatic brain injury of different severities on emotional, cognitive, and oxidative stress-related parameters in mice. J Neurotrauma (2010) 1.00
Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease. J Neural Transm (Vienna) (2010) 0.84
Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease. Ann N Y Acad Sci (2009) 0.80
Central nervous system activity of the proanthocyanidin-rich fraction obtained from Croton celtidifolius in rats. J Pharm Pharmacol (2010) 0.79
Effects of acute administration of the hydroalcoholic extract of mate tea leaves (Ilex paraguariensis) in animal models of learning and memory. J Ethnopharmacol (2008) 0.78
Adenosine A2b receptors control A1 receptor-mediated inhibition of synaptic transmission in the mouse hippocampus. Eur J Neurosci (2015) 0.77
Rosmarinus officinalis L. hydroalcoholic extract, similar to fluoxetine, reverses depressive-like behavior without altering learning deficit in olfactory bulbectomized mice. J Ethnopharmacol (2012) 0.76
Mild cognitive deficits associated to neocortical microgyria in mice with genetic deletion of cellular prion protein. Brain Res (2008) 0.76
Exercise Improves Cognitive Impairment and Dopamine Metabolism in MPTP-Treated Mice. Neurotox Res (2016) 0.75
In athletes with mild intermittent asthma, is a beta-2 agonist 15-30 minutes prior to activity more effective at preventing an asthma attack than a daily inhaled steroid? J Okla State Med Assoc (2012) 0.75